Furthermore, SIK2 has been identified as a centrosome kinase regulating the G2-M transition, and its depletion or inhibition sensitizes ovarian cancer to paclitaxel-based chemotherapy [10,12]. Here, SIK2 is linked to ovarian carcinoma.